Radial Extracorporeal Shock Wave Therapy Versus Platelet-rich Plasma Injection for Greater Trochanteric Pain Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04537091 |
|
Recruitment Status :
Completed
First Posted : September 3, 2020
Last Update Posted : February 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Greater trochanteric pain syndrome (GTPS), is characterised by pain around the greater trochanter. Failure of first-line management for GTPS is followed by second-line treatments range from extracorporeal shock wave therapy (ESWT), corticosteroid or platelet-rich plasma (PRP) injections, and surgery. In a systematic reviews, PRP seems a viable effective and safe alternative option for GTPS after failed physical therapy. Also, positive results from previous systematic reviews involving radial ESWT (rESWT) as a treatment for GTPS.
In the literature review, there is no comparison of the effectiveness of ESWT and PRP injection in patients with GTPS. The aim of this study was to investigate the effects of rESWT and PRP injection on pain, hip disability, and quality of life in patients with GTPS
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Gluteal Tendinopathy Greater Trochanteric Pain Syndrome | Procedure: rESWT Procedure: PRP injection | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Investigator, Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | Radial Extracorporeal Shock Wave Therapy Versus Platelet-rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome With Gluteal Tendinopathy: a Randomized Controlled Trial |
| Actual Study Start Date : | August 1, 2020 |
| Actual Primary Completion Date : | December 1, 2020 |
| Actual Study Completion Date : | January 5, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ESWT group: rESWT
rESWT treatment was applied to patients
|
Procedure: rESWT
rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel |
|
Experimental: PRP group: PRP injection
PRP treatment was applied to patients
|
Procedure: PRP injection
PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography. |
- Harris Hip Score (HHS) [ Time Frame: Changes from baseline in Harris Hip Score to 1 month and 6 months. ]The index consists of questions about pain and activities of daily living, referring to the previous week, and assessments of hip function (limping) and range of motion. Score ranges from 100 (no disability) to 0 (maximum disability).
- Visual Analog Scale (VAS) [ Time Frame: Changes from baseline in Visual Analog Scale score to 1 month and 6 months. ]The self-evaluation of pain severity during rest and activity in the previous week was calculated using a 10-cm VAS scale, where 0 in the left corner of the scale represented 'no pain' and 10 in the right corner represented 'the worst pain that could be imagined'
- The Roles and maudsley (RM) [ Time Frame: Changes from baseline in Roles and maudsley score to 1 month and 6 months. ]RM score was used to evaluate pain and activity limitation as classified in four categories: 1 point = excellent, 2 points = good, 3 points = fair, and 4 points = poor.
- EuroQol five-dimensional questionnaire (EQ-5D-3L) [ Time Frame: Changes from baseline in EuroQol five-dimensional questionnaire score to 1 month and 6 months. ]The EQ-5D-3L scale, which scores five health conditions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) through evaluation at 3 levels (no problems, some problems, or extreme problems), was used to evaluate the quality of life.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- > 18 years old
- Complaining of pain located anterior, lateral or posterior to the great trochanter for more than 3 months
- Pain while lying on the affected side
- Local tenderness on palpation of the area of the great trochanter
- MRI evidence of gluteus minimus or medius tendinopathy
- Refractory to conservative management
Exclusion Criteria:
- Presence of signs and symptoms of another cause of regional hip pain.
- Full-thickness tear of the involved gluteal tendons, bursa, and intra-articular structures
- Evidence of concomitant injury to the involved lower extremity, including radiculopathy or radiculitis, ischial tuberosity avulsion
- Severe knee or hip osteoarthritis
- Previous hip surgery or use of ESWT for GTPS.
- Acute low back pain
- Implanted pacemaker
- Vascular, neurologic, rheumatic diseases.
- Any neoplastic disorders
- Blood coagulation disorders or use of antiplatelet or anticoagulant drugs
- Pregnancy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04537091
| Turkey | |
| Istanbul Physical Medicine and Rehabilitation Training and Research Hospital | |
| Istanbul, Bahcelievler, Turkey, 34180 | |
| Study Chair: | Mustafa Corum, MD | Istanbul Physical Medicine Rehabilitation Training & Research Hospital |
| Responsible Party: | Mustafa Corum, Principal Investigator, Istanbul Physical Medicine Rehabilitation Training and Research Hospital |
| ClinicalTrials.gov Identifier: | NCT04537091 |
| Other Study ID Numbers: |
2020-309 |
| First Posted: | September 3, 2020 Key Record Dates |
| Last Update Posted: | February 10, 2021 |
| Last Verified: | September 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Tendinopathy Bursitis Syndrome Somatoform Disorders Disease Pathologic Processes |
Mental Disorders Muscular Diseases Musculoskeletal Diseases Tendon Injuries Wounds and Injuries Joint Diseases |

